Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGE™ platform.

Before release into the clinic mRNA therapeutics need comprehensive characterization. In this eBlog we review key quality attributes of mRNA therapeutics.

miRNAs are key regulators of expression and translation, however identifying where and how they bind can be a challenge. In this eBlog we reveal how miR-eCLIP can be used to directly profile miRNA activity.

mRNA therapeutics are revolutionizing medicine but the design of an effective RNA can be challenging. In this eBlog we review key design factors.